| Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ... Nature medicine 20 (11), 1301-1309, 2014 | 1063 | 2014 |
| Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? L Arnould, M Gelly, F Penault-Llorca, L Benoit, F Bonnetain, C Migeon, ... British journal of cancer 94 (2), 259-267, 2006 | 700 | 2006 |
| Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis F Moinfar, YG Man, L Arnould, GL Bratthauer, M Ratschek, FA Tavassoli Cancer research 60 (9), 2562-2566, 2000 | 518 | 2000 |
| Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review E Luporsi, F André, F Spyratos, PM Martin, J Jacquemier, ... Breast cancer research and treatment 132, 895-915, 2012 | 421 | 2012 |
| Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory … S Ladoire, L Arnould, L Apetoh, B Coudert, F Martin, B Chauffert, ... Clinical cancer research 14 (8), 2413-2420, 2008 | 389 | 2008 |
| Pathology of ovarian cancers in BRCA1 and BRCA2 carriers SR Lakhani, S Manek, F Penault-Llorca, A Flanagan, L Arnout, S Merrett, ... Clinical Cancer Research 10 (7), 2473-2481, 2004 | 378 | 2004 |
| In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival S Ladoire, G Mignot, S Dabakuyo, L Arnould, L Apetoh, C Rébé, ... The Journal of pathology 224 (3), 389-400, 2011 | 274 | 2011 |
| CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? T Petrella, S Dalac, M Maynadié, F Mugneret, E Thomine, P Courville, ... The American journal of surgical pathology 23 (2), 137-146, 1999 | 241 | 1999 |
| Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients M Cordonnier, C Nardin, G Chanteloup, V Derangere, MP Algros, ... Journal of extracellular vesicles 9 (1), 1710899, 2020 | 207 | 2020 |
| [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy A Berriolo-Riedinger, C Touzery, JM Riedinger, M Toubeau, B Coudert, ... European journal of nuclear medicine and molecular imaging 34, 1915-1924, 2007 | 201 | 2007 |
| Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients A Hennequin, V Derangere, R Boidot, L Apetoh, J Vincent, D Orry, ... Oncoimmunology 5 (2), e1054598, 2016 | 191 | 2016 |
| Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors. S Reveneau, L Arnould, G Jolimoy, S Hilpert, P Lejeune, V Saint-Giorgio, ... Laboratory investigation; a journal of technical methods and pathology 79 …, 1999 | 191 | 1999 |
| Clinical value of mitochondrial mutations in colorectal cancer A Lièvre, C Chapusot, AM Bouvier, F Zinzindohoué, F Piard, P Roignot, ... Journal of Clinical Oncology 23 (15), 3517-3525, 2005 | 187 | 2005 |
| Chronic high-fat diet affects intestinal fat absorption and postprandial triglyceride levels in the mouse V Petit, L Arnould, P Martin, MC Monnot, T Pineau, P Besnard, I Niot Journal of lipid research 48 (2), 278-287, 2007 | 177 | 2007 |
| Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy S Ladoire, L Arnould, G Mignot, B Coudert, C Rébé, F Chalmin, J Vincent, ... Breast cancer research and treatment 125, 65-72, 2011 | 175 | 2011 |
| Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer L Arnould, Y Denoux, G MacGrogan, F Penault-Llorca, M Fiche, I Treilleux, ... British journal of cancer 88 (10), 1587-1591, 2003 | 174 | 2003 |
| Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2–overexpressing stage II or III … BP Coudert, R Largillier, L Arnould, P Chollet, M Campone, D Coeffic, ... Journal of clinical oncology 25 (19), 2678-2684, 2007 | 166 | 2007 |
| Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification CKY Ng, LG Martelotto, A Gauthier, HC Wen, S Piscuoglio, RS Lim, ... Genome biology 16, 1-21, 2015 | 155 | 2015 |
| A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers A Ferrari, A Vincent-Salomon, X Pivot, AS Sertier, E Thomas, L Tonon, ... Nature communications 7 (1), 12222, 2016 | 153 | 2016 |
| Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant … B Coudert, JY Pierga, MA Mouret-Reynier, K Kerrou, JM Ferrero, T Petit, ... The Lancet Oncology 15 (13), 1493-1502, 2014 | 151 | 2014 |
Bruno CoudertCentre Georges Francois Leclerc Dijon FranceVerified email at cgfl.fr